Sirio Pharma Co., Ltd.
SZSE:300791.SZ
30.67 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 4,211.064 | 3,582.022 | 2,507.262 | 2,368.948 | 2,066.818 | 1,579.562 | 1,595.4 | 1,330.465 | 786.194 | 824.44 | 778.604 | 698.677 | 553.772 |
| Cost of Revenue
| 2,886.115 | 2,497.912 | 1,725.557 | 1,593.733 | 1,393.012 | 1,059.191 | 1,042.4 | 891.504 | 531.674 | 470.28 | 464.151 | 433.964 | 366.833 |
| Gross Profit
| 1,324.948 | 1,084.111 | 781.705 | 775.215 | 673.806 | 520.371 | 552.999 | 438.961 | 254.519 | 354.16 | 314.453 | 264.712 | 186.939 |
| Gross Profit Ratio
| 0.315 | 0.303 | 0.312 | 0.327 | 0.326 | 0.329 | 0.347 | 0.33 | 0.324 | 0.43 | 0.404 | 0.379 | 0.338 |
| Reseach & Development Expenses
| 114.957 | 110.495 | 80.716 | 83.19 | 64.711 | 65.785 | 62.063 | 45.512 | 40.848 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 154.855 | 137.58 | 143.515 | 74.368 | 65.276 | 56.709 | 37.795 | 34.125 | 31.009 | 144.043 | 103.692 | 84.088 | 56.982 |
| Selling & Marketing Expenses
| 154.26 | 98.624 | 130.134 | 148.857 | 122.321 | 129.537 | 108.477 | 103.987 | 71.96 | 114.904 | 118.053 | 93.11 | 61.028 |
| SG&A
| 309.115 | 626.886 | 273.649 | 223.225 | 187.596 | 186.246 | 146.273 | 138.112 | 102.969 | 258.947 | 221.745 | 177.198 | 118.01 |
| Other Expenses
| 562.889 | 58.503 | -13.538 | -8.914 | -3.192 | 4.75 | 2.144 | 4.702 | 4.406 | 0.937 | 0.226 | -3.377 | -0.405 |
| Operating Expenses
| 997.941 | 802.086 | 522.41 | 480.328 | 368.992 | 358.561 | 299.293 | 281.223 | 201.222 | 266.083 | 227.407 | 182.859 | 122.598 |
| Operating Income
| 327.007 | 282.025 | 265.056 | 289.815 | 315.612 | 151.692 | 228.238 | 125.887 | 933.067 | 69.69 | 74.037 | 69.692 | 54.822 |
| Operating Income Ratio
| 0.078 | 0.079 | 0.106 | 0.122 | 0.153 | 0.096 | 0.143 | 0.095 | 1.187 | 0.085 | 0.095 | 0.1 | 0.099 |
| Total Other Income Expenses Net
| -10.353 | -8.768 | -13.538 | -8.914 | -3.648 | 5.206 | 2.144 | 4.702 | 4.406 | 0.937 | 0.174 | -4.025 | -0.443 |
| Income Before Tax
| 316.654 | 273.257 | 251.518 | 280.901 | 311.964 | 156.898 | 230.382 | 130.589 | 937.473 | 70.627 | 74.211 | 65.667 | 54.379 |
| Income Before Tax Ratio
| 0.075 | 0.076 | 0.1 | 0.119 | 0.151 | 0.099 | 0.144 | 0.098 | 1.192 | 0.086 | 0.095 | 0.094 | 0.098 |
| Income Tax Expense
| 34.636 | 32.969 | 39.233 | 49.066 | 54.598 | 14.373 | 27.157 | 26.289 | 233.747 | 14.361 | 12.762 | 11.119 | 9.045 |
| Net Income
| 325.062 | 281.039 | 212.286 | 231.834 | 257.366 | 142.525 | 203.225 | 104.3 | 703.726 | 56.267 | 61.449 | 54.548 | 45.333 |
| Net Income Ratio
| 0.077 | 0.078 | 0.085 | 0.098 | 0.125 | 0.09 | 0.127 | 0.078 | 0.895 | 0.068 | 0.079 | 0.078 | 0.082 |
| EPS
| 1.39 | 1.2 | 1.18 | 1.29 | 1.43 | 0.79 | 1.51 | 0.77 | 5.21 | 0.42 | 0 | 0 | 0 |
| EPS Diluted
| 1.39 | 1.2 | 1.17 | 1.29 | 1.43 | 0.79 | 1.51 | 0.77 | 5.21 | 0.42 | 0 | 0 | 0 |
| EBITDA
| 634.662 | 592.071 | 432.136 | 402.678 | 396.64 | 247.028 | 299.573 | 189.911 | 982.543 | 117.048 | 113.629 | 100.973 | 79.953 |
| EBITDA Ratio
| 0.151 | 0.165 | 0.172 | 0.17 | 0.192 | 0.156 | 0.188 | 0.143 | 1.25 | 0.142 | 0.146 | 0.145 | 0.144 |